Extended Follow-Up Analysis of First-Line Atezolizumab in Extensive-Stage Small Cell Lung Cancer: A Real-World Multicenter Prospective Cohort Study
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q2Scopus Q2
- 저널
- THORACIC CANCER16(23) · 2025
- 피인용
- Web of Science 0Scopus 0
- FWCI (Scopus)
- 0
- JCR IF
- JCR 2024 2.3
- ISSN
- 1759-7706
저자
- Song, Yechan제1저자Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pulm & Crit Care Med, Seoul, South Korea
- Choi, Myeong GeunUniv Ulsan, Coll Med, Asan Med Ctr, Dept Pulm & Crit Care Med, Seoul, South Korea
- Kim, Yeon JooEulji Univ, Nowon Eulji Med Ctr, Sch Med, Dept Pulmonol, Seoul, South Korea
- Lee, Jae CheolUniv Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
- Ji, WonjunUniv Ulsan, Coll Med, Asan Med Ctr, Dept Pulm & Crit Care Med, Seoul, South Korea
- Oh, In-JaeChonnam Natl Univ, Chonnam Natl Univ Hwasun Hosp, Med Sch, Dept Internal Med, Hwasun, South Korea
- Lee, Sung YongKorea Univ, Guro Hosp, Dept Internal Med, Div Pulm Allergy & Crit Care Med,Coll Med, Seoul, South Korea
- 윤성훈Pusan Natl Univ, Yangsan Hosp, Dept Internal Med, Div Pulmonol Allergy & Crit Care Med, Yangsan, South Korea
- Lee, Shin YupKyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea
- Lee, Jeong EunChungnam Natl Univ, Coll Med, Dept Internal Med, Div Pulmonol, Daejeon, South Korea
- Kim, Eun YoungYonsei Univ, Severance Hosp, Dept Internal Med, Div Pulm & Crit Care Med,Coll Med, Seoul, South Korea
- Kim, Ho YoungHallym Univ, Sacred Heart Hosp, Dept Internal Med, Div Hematol & Oncol, Anyang, South Korea
- Choi, Chang-Min교신저자Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pulm & Crit Care Med, Seoul, South Korea
초록
Background: We previously reported the short-term real-world effectiveness and safety of first-line atezolizumab combined with chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC). This study provides an updated analysis of the effectiveness, prognostic factors, and subsequent treatment patterns in first-line immunochemotherapy. Methods: This prospective multicenter observational study enrolled patients with ES-SCLC, diagnosed at seven university hospitals throughout Korea, between June 2021 and August 2022. Primary outcomes were 1-year overall survival (OS) and progression-free survival (PFS), whereas secondary outcomes included OS, objective response rate, disease control rate, second progression-free survival, and safety, evaluated based on established clinical guidelines. Results: A total of 100 ES-SCLC patients (median age, 69 years) were enrolled, with a median follow-up duration of 26.0 months. The median PFS and OS were 6.2 and 17.1 months, respectively, with a 1-year OS rate of 62.5%. Favorable prognostic factors for OS included partial response (PR) and stable disease (SD) as the best responses (SD: hazard ratio (HR), 0.79; PR: HR, 0.38) and a longer platinum-free interval (HR 0.84). Brain radiotherapy significantly improved OS in patients with brain metastases, whereas thoracic radiotherapy during first-line treatment tended to prolong survival in patients who responded to systemic treatment. Patients receiving second-line treatment after progression presented a significantly longer OS than did those receiving only best supportive care. Conclusion: This study outlined the real-world effectiveness and safety of first-line atezolizumab immunochemotherapy for ES-SCLC patients over an extended follow-up, noting that local treatment and post-progression therapy were associated with improved survival.
키워드
식별자
- Scopus EID
- 2-s2.0-105024698682
- WoS UID
- 001636820100001



로그인
연구물 목록으로